Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small cell lung cancer: Results of a phase 1/2 trial: Comment

Joe Y. Chang

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small cell lung cancer: Results of a phase 1/2 trial: Comment'. Together they form a unique fingerprint.